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lectroconvulsive therapy (ECT) is the safe induc-
tion of a series of generalized epileptic seizures for thera-
peutic purposes,using brief-pulse stimulation techniques
under anesthesia and muscle paralysis.Informed consent
of the patient or the responsible legal guardian is manda-
tory.In cases of life-threatening diseases where there is no
possibility of obtaining informed consent due to the char-
acter of the mental illness,ECT can also be administered
after legal authorization and the informed consent of the
patients’ legal representatives. Patients in stupor, manic
excitement,catatonic mutism,and acute paranoid states
may not be able to provide written consent,and alternative
consent processes which vary with jurisdictions in different
countries must be applied.It is useful for physicians,who
are responsible for the more acute and severely ill psychi-
atric patients,to consider ECT as a primary indication,and
to be acquainted with all the means for proper consent for
treatment within their jurisdiction.Table I shows the WHO
recommendations on administration of ECT.
Since the earliest publications on the subject,the excellent
therapeutic effectiveness of this method in the treatment
of depression and other psychiatric disorders has been
described in a variety of reviews and meta-analyses.
2-4
However,although the technique and practice of ECT has
improved considerably in the last decades,the crucial neu-
robiological mechanisms contributing to the therapeutic
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In spite of recent developments in the pharmacotherapy
of depressive disorders, the delay until clinical improve-
ment can be achieved, and the considerable rate of non-
response and nonremission, are major problems which
remain unresolved. Electroconvulsive therapy (ECT) is a
nonpharmacologic biological treatment which has been
proven to be a highly effective treatment option, pre-
dominantly for depression, but also for schizophrenia and
other indications. Though there is a lack of controlled
investigations on long-term treatments, ECT can also be
used for relapse prevention during maintenance thera-
pies. The safety and tolerability of electroconvulsive treat-
ment have been enhanced by the use of modified stimu-
lation techniques and by progress in modern anesthesia.
Thus, today a safe treatment can also be offered to
patients with higher somatic risks. ECT still represents an
important option, especially in the therapy of treatment-
resistant psychiatric disorders after medication treatment
failures. Earlier consideration of ECT may reduce the rate
of chronic and difficult-to-treat psychiatric disorders.   
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Although decades of research and clinical experience
have improved the technique and practice of ECT, the
underlying crucial mechanisms which contribute to the
superior therapeutic effects of ECT are still under
investigation. Most research investigating the neurobi-
ological effects of ECT focused on the antidepressant
potential of ECT, and revealed that ECT particularly
affects neurotransmitter systems which may be involved
in the pathophysiology of depression.
5 In accordance
with the monoamine deficiency hypothesis in depres-
sion,several studies indicated that ECT attenuates sero-
tonergic and noradrenergic neurotransmission.
However, animal studies revealed conflicting results,
such as an enhanced sensitivity of presynaptic hip-
pocampal serotonin (5-HT)1Areceptors,
6 but also a
decreased sensitivity of hippocampal 5-HT1Areceptors,
7
have been described after electroconvulsive shocks
(ECS) in rats.However,in patients suffering from major
depression, ECT has been shown to increase trypto-
phan plasma levels
8,9 suggesting that an increased avail-
ability of the serotonin precursor may contribute to the
therapeutic effects of ECT.
9
In addition, a compensatory increase in γ-aminobutyric
acid (GABA) neurotransmission has been suggested as
a possible mechanism of ECT. In line with the anticon-
vulsant effects of ECT and the GABA-deficit hypothe-
sis of depression,
10 a proton magnetic resonance spec-
troscopy study showed that occipital cortex GABA con-
centrations
11 are increased in depressed patients treated
with ECT. Furthermore, an iomazenil-single-photon
emission computer tomography (SPECT) study sug-
gested an enhanced GABAergic neurotransmission as a
possible mechanism of ECT.
12 Recently, ECT has been
shown to enhance activity of inhibitory circuits in human
motor cortex, further indicating that ECT has marked
effects on GABAergic neurotransmission.
13
Due to the fact that ECT increased glutamate plasma
levels
9 and normalized reduced glutamate/glutamine lev-
els in the left cingulum in depressed patients responding
to ECT,
14 effects on glutamate, an excitatory neuro-
transmitter,may also play a role.
In addition to effects on neurotransmitter systems,ther-
apeutic effects of ECT have also been attributed to its
influence on the hypothalamic-pituitary-adrenal (HPA)
axis.A dysregulation of the HPA axis comprising ele-
vated levels of corticotrophin-releasing hormone
(CRH),adrenocorticotropic hormone (ACTH),and cor-
tisol during depressive episodes,which normalizes after
clinical remission, is one of the most consistent biologi-
cal findings in depressive disorders.
15Acute elevations of
ACTH and cortisol plasma levels have been observed
immediately after ECT,
16,17 and might be interpreted as
a physiological stress response. However, during the
course of ECT,ACTH and cortisol plasma levels have
been found to decrease, suggesting that a downregula-
tion of the HPA axis
18 might comprise a therapeutic
effect of ECT in major depression.
In recent decades, considerable evidence has emerged
that neuroactive steroids,which alter neuronal excitabil-
ity via nongenomic mechanisms, might be involved in
the pathophysiology of depression,and might contribute
to the therapeutic effects of antidepressants.
19Although
no alterations of positive GABAergic 3α-reduced neu-
roactive steroids have been detected in depressed
patients after treatment with ECT,
20 elevated plasma lev-
els of dehydroepiandrosterone sulfate (DHEAS),which
is a potent negative modulator of the GABA-A recep-
tor,have been found in psychotic depressed patients and
were associated with nonresponse to ECT these
patients.
21Therefore,it has been suggested that DHEAS
plasma levels might serve as a predictive marker of non-
responsiveness to ECT.
21 In a genetic rat model of
depression, DHEAS pretreatment abolished the anti-
depressant effects of ECS, suggesting that a pharmaco-
logically induced decrease in DHEAS levels might serve
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• According to WHO recommendations, as with any other 
treatment, ECT should only be administered after obtaining 
informed consent.
• ECT should only be administered in the so-called “modified 
form” (which to date represents a standard procedure), ie, 
with the use of anesthesia and muscle relaxation.
• The practice of using unmodified ECT should be stopped, 
but currently this method still is in use in some countries, 
due to local habits and financial resources.
Table I. The administration of ECT according to WHO recommenda-
tions.
1as a putative intervention to restore the treatment
response in depressed patients resistant to ECT.
22
Recently, growing evidence has emerged for a major
role of downstream signal transduction pathways, eg,
the cyclo-adenosine monophosphate (AMP)-responsive
element binding protein (CREB) cascade, and their
effects on neurotrophic factors such as brain-derived
neurotrophic factor (BDNF) in the pathogenesis and
treatment of depressive disorders.
23 In this context, in
vivo and animal studies suggested that the antidepres-
sant effects of ECS may be attributed to its putative
effects on neurogenesis and neuroplasticity.Single ECS
have been shown to increase BDNF mRNA
24-26 and
tyrosine kinase B (TrkB) mRNA, which is an effector
of BDNF.
25 Furthermore, comparable to the observa-
tions after pharmacological antidepressant treatment,
27
BDNF mRNA and TrkB mRNA are continuously
increased after a course of ECS.
28 Moreover, several
studies have indicated that ECS increase synaptic con-
nectivity.Chronic ECS induce mossy fiber sprouting in
the hippocampus
29,30 and in other brain regions such as
amygdala and frontal areas.
31 In addition, ECS are fol-
lowed by an increase in neuron formation in the hip-
pocampus,
30,32,33 an effect that was already observed after
a single ECS
33 but which was even more pronounced
after a series of ECS,
32,33 suggesting a dose-dependent
mechanism of ECT on neurogenesis.
32 In addition,
increased levels of CREB and an enhanced transcrip-
tion mediated by CREB have been detected in hip-
pocampus after ECS in experimental animals.
27
SPECT studies in depressed patients indicated a
reduced cerebral blood flow (CBF) in frontal areas
briefly after ECT.
34 In contrast to these acute effects,
CBF has been shown to increase and therefore to nor-
malize in depressed patients after a course of ECT.
12,35 In
frontal and parietal cortex,and in anterior and posterior
cingulate gyrus of depressed patients, a decreased
regional cerebral glucose metabolism has been observed
after ECT.
36,37 Responders compared with nonresponders
had reduced cerebral glucose metabolism in frontal
regions,
38 suggesting that the decrease in glucose metab-
olism might contribute to the therapeutic effects of
ECT.
36
Nevertheless,in spite of the increasing knowledge about
the central nervous system effects, the single or com-
bined mechanisms crucial for therapeutic efficacy of
ECT in divergent psychiatric disorders are not yet
known.
The priority of ECT in the treatment 
of psychiatric disorders
ECT as first-line treatment
Depressive stupor and inanition,as in melancholic,cata-
tonic,or psychotic depression,can be a first-line indication
for ECT before other treatments are prescribed.Because
ECT has been shown to be associated with a fast relief of
symptoms,
39 this is essential in case of severe psychomotor
retardation or refusal of food and drink.In case of severe
psychotic symptoms and high suicide risk,ECT should be
considered earlier than other therapeutic options.
40 In psy-
chotic depression,the remission rate for ECT approaches
90%,with relief experienced within 10 to 14 days.
41,42The
risks of suicide that mark severe psychiatric illnesses are
quickly relieved by ECT,although attention to continua-
tion treatments is essential to sustain the benefit.
43Also
other acute psychiatric syndromes such as severe excite-
ment,eg,in delirious mania,malignant catatonia,and neu-
roleptic malignant syndrome (NMS) may require ECT as
a first-line treatment.
2,3This is especially true if the clinical
differentiation between NMS and malignant catatonia is
not possible.Intensive ECT,usually administered daily (en
bloc),relieves the high rates of mortality associated with
malignant catatonia and delirious mania.
44,45 In addition,
when depression,mania,and psychotic symptoms accom-
pany systemic illnesses or are present during early preg-
nancy or the postpartum breast-feeding period,the admin-
istration of medications is often precluded, and ECT
becomes a useful treatment option.In the case of severe
and life-threatening adverse events of medication,ECT
monotherapy can be a safe first-line treatment.This is also
true for patients suffering from severe somatic diseases
with a risk of worsening due to antidepressant or antipsy-
chotic pharmacotherapy.
46-48
Long duration and a chronic course of psychiatric disor-
ders are negative outcome variables predicting higher
risks for treatment resistance against both medication
and ECT.
46,49 More patients should therefore be informed
about enhanced response rates in case of ECT adminis-
tration in comparison with pharmacotherapy alone to be
involved properly in shared decision-making concerning
their treatment.Nevertheless,the primary use of ECT is
handicapped by the severe stigma and even legal restric-
tions against its use in some jurisdictions.
41 It is useful for
practitioners who are responsible for the more acute and
severely ill psychiatric patients to consider ECT as a pri-
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for proper consent for treatment within their jurisdiction.
ECT as second-line treatment
Even if patients receive ECT only in rare cases immedi-
ately after attaining criteria for pharmacotherapy resis-
tance,those treatment failures are the most frequent ECT
indication.
50-53The utilization of ECT enhances response
rates significantly.
54-56This is especially true in patients suf-
fering from psychotic depression,even if antipsychotic ther-
apies have been adequately applied.
40,57 Intolerable side
effects of antidepressant medications,somatic comorbidi-
ties emerging during the pharmacological treatment,
40,58 or
worsening of depressive symptoms,including severe sui-
cidality during antidepressant pharmacotherapy, can be
also the cause of initiating an ECT treatment course.
40
ECT as “last-resort” treatment
For rare last-resort indications,no scientific evidence derived
from randomized controlled trials (RCTs) demonstrating
the efficacy of ECT can be found in the scientific literature.
Nevertheless anecdotal case reports,case series,and retro-
spective reviews suggest the clinical effectiveness of ECT in
obsessive-compulsive disorder (OCD) after multiple treat-
ment failures utilizing pharmacotherapeutic and psy-
chotherapeutic approaches.Also,in a patient suffering from
Tourette's syndrome,a rapid and sustained relief of symp-
toms has been reported.
59 In the case of treatment-resistant




only depressive symptoms but also impaired motor func-
tion in Parkinson’s disease show amelioration after a course
of electroconvulsive treatment (for review see ref 62).
Of course,particularly in such rare cases with last-resort
indications,an individual benefit/risk estimation,includ-
ing the complete evaluation of prior treatment failures,
has to be done for each patient.
First- and second-line indications and rare last resort
indications are summarized in Table II.
ECT in the treatment of depressive disorders
Efficacy of ECT in the acute treatment of depression
under specific diagnostic, comorbid, and somatic
conditions
Unipolar depression
The general efficacy and superiority of ECT in compar-
ison with antidepressant pharmacotherapy has been
Clinical research
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Table II. Indications for electroconvulsive therapy (ECT). *, ref 45; **, with suicidality which can not be handled even on protected wards, psychotic
symptoms, depressive stupor, with positive symptoms or acute danger of self-harm or harm of others, or with severe reduction in oral intake;
***, ref 63
Category of ECT indications Indication
ECT as a first-line treatment • febrile catatonia*
• malignant neuroleptic syndrome*
• severe depressive episode**
• schizoaffective psychosis**
• schizophrenia**, ***
• in case of life-threatening or intolerable side effects of psychopharmacological treatments





• depression or psychotic symptoms in case of organic diseases
ECT as a last-resort treatment • treatment-resistant obsessive compulsive disorder (OCD)
• treatment-resistant dyskinesias
• treatment-resistant Gilles de la Tourette syndrome
• treatment resistant epilepsy
• Parkinson’s disease (treatment-resistant)described in controlled clinical trials and meta-analyses.
4
Response rates between 80% and 90%
49,51 and even
100%,
64 have been reported.Also,lower response rates
of about 50% to 60% have been described in patients
receiving unilateral ECT after several medication treat-
ment failures.
64 Nevertheless,in a recent study,sustained
response rates of 80%, superior to pharmacotherapy
response rates (up to 70%),and remission rates of 75%
(up to 87% for study completers suffering from psychotic
depression) have been found in major depressed patients
treated with optimized ECT.
42,43,65,66
A 20% improvement in comparison with tricyclic anti-
depressants and a 45% improvement in comparison with
monoamine oxidase inhibitors (MAOIs),
67 as well as a
better improvement in comparison with the selective
serotonin reuptake inhibitor (SSRI) paroxetine,
57 have
been described.In addition,a more rapid improvement
in comparison with pharmacotherapeutic approaches has
been reported.
2,14,42,68 Most patients show a faster treat-
ment response during ECT in comparison with pharma-
cotherapy.
69An advantage concerning speed of response
in similar efficacious pharmacotherapeutic approaches
such as lithium augmentation
68 after tricyclic antidepres-
sant (TCA) treatment failures has also been described.
In particular, in patients receiving ECT after pharma-
cotherapy treatment failures,longer treatment intervals
until complete remission have to be expected.
In former studies in which lower stimulation energy has
been used, bilateral ECT has been shown to be more
effective than unilateral ECT.
4,68,69 In addition,unilateral
ECT may achieve efficacy rates equal to those of bilat-
eral ECT if the dose regime is 6 to 8 times above the
titrated seizure threshold.
64,70 In this case the requirement
of a calibration session,probably ineffective for antide-
pressant treatment, can slow down the decrease in
depressive symptoms. In addition, cognitive adverse
events are identical to those of bilateral ECT.
Bipolar disorder
Bipolar depression
ECT is an effective antidepressant therapy,regardless of
whether depressive episodes occur due to major depres-
sive disorder (MDD) or bipolar disorder.
2,40An enhanced
switch risk, including the occurrence of hypomania or
mania, can be observed during every highly effective
antidepressant treatment. Infrequent switches from
depression to mania may also occur during the course of
ECT,
40,71 but due to missing randomized controlled trials
and switch rates of up to 30% regardless of antidepres-
sant therapies,this clinical observation also has been dis-
cussed as an artifact.
72 Contrary to antidepressant phar-
macotherapy,the treatment does not have to be stopped,
due to the antimanic properties of ECT. Furthermore
ECT may be combined with lithium treatment to aug-
ment lithium effects and to prevent the switch to mania
in high-risk patients. In this case an enhanced risk for
cognitive and medical side effects has to be taken into
account.
73 Even a combined use of ECT and anticonvul-
sants in case of urgent indications for mood stabilizers is
possible,and may yield clinical advantages.
73,74,55
Mania
Due to the availability of lithium,other mood stabilizers,
classical neuroleptics,and atypical antipsychotics which
exert good antimanic effectiveness, the primary treat-
ment of mania using ECT nowadays is a rare event.This
is true even if good efficacy has been shown in several
RCTs
76 and the treatment has been recommended in sev-
eral reviews (eg, ref 77).A high remission or improve-
ment rate of 80%
77 has been reported,even if prior phar-
macotherapeutic approaches have shown only poor
response.Moreover,superiority of ECT in comparison
with lithium or antipsychotics has been reported.
78,79
Concerning the treatment modalities,predominantly a
superiority of bilateral ECT in comparison with unilat-
eral stimulation techniques has been reported.
80,81
Dysthymia and double depression
Chronic depression in case of dysthymia alone is not an
indication for ECT treatment.Nevertheless,if the diag-
nostic criteria for MDD or double depression are pre-
sent, dysthymia is not a predictor of a poor ECT
response.
2,40
Depressive syndromes in OCD
In patients suffering from OCD not responsive to phar-
macotherapy,response after ECT may be expected,pre-
dominantly if OCD is accompanied by depressive symp-
toms,
40 which is often the case. In addition, in case of
treatment-refractory OCD,improvements occurred inde-
pendently of depression scores and were long-lasting in
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82Also,the beneficial use of ECT during
OCD continuation therapy has been reported.
40
Comorbid personality disorder
Comorbid personality disorder is a predictor of poor
response to ECT, and the recommendation for ECT
should be cautious in such cases.
2,64 Nevertheless, ECT
should not be withheld from patients suffering from
MDD with comorbid personality disorders in case of
pharmacotherapy resistance.
40 The information about
lower response rates has to be included in the patient
information about the estimated treatment outcome.
Organic depression due to somatic disorders
Patients suffering from secondary depression associated
with somatic diseases show lower response rates to bio-
logical therapies such as pharmacotherapy or ECT
83-85 in
comparison with MDD. Nevertheless ECT is clinical
effective in patients suffering from depression after cere-
bral infarction (“poststroke depression”).
64,69,84 However,
particularly in this patient group,organic risk factors have
to be considered thoroughly during interdisciplinary neu-
rologic and psychiatric evaluations.
ECT in old age
ECT has also been shown to have excellent effectiveness
in geriatric patients. Response rates were better in
younger than in older geriatric patients.
2;86,87 Despite spe-
cific side effects such as greater cognitive impairment,
efficacy was generally greater in geriatric than in young
patients, and a reduced mortality in comparison with
other treatments has been shown.
88 Further progression
in understanding of ECT and anesthesia has reduced the
risks of ECT. So some authors now are of the opinion
that the use of modified ECT in geriatric patients,par-
ticularly in patients at medical risk,can be encouraged
now.
2,44
Combination of ECT and antidepressants
Clinical effectiveness
In spite of the greater efficacy and clinical effectiveness
of ECT in comparison with pharmacotherapy, not all
patients respond to conventional ECT monotherapy.
The majority of patients referred for ECT have had
multiple trials of medication; this may reduce the
response rate to ECT.The use of bilateral or high-dose
unilateral stimulation can enhance the effectiveness of
ECT.
64,65A further option to augment an ECT treatment
course may be the concomitant prescription of antide-
pressants.This may be necessary due to possible non-
responsiveness to ECT in 15% to 25% of depressed
patients.
65 However, study results on a putative benefit
combining ECT with tricyclic antidepressants,
89,90 and
the lack of advantages of other concomitant medication
like selective serotonin reuptake inhibitors (SSRIs) are
still controversial.
89 In particular,the efficacy of modern
antidepressants in combination with ECT,eg,the dually
acting substances mirtazapine and venlafaxine, has
never been investigated in controlled studies.
Nevertheless,retrospective chart analyses suggest ben-
eficial effects during an ECT/antidepressant combina-
tion treatment.
91
In patients after medication treatment failures,the clini-
cal recommendation is to combine ECT with antide-
pressants at moderate doses.This is possible during the
whole treatment course or at least during the last 2 weeks
of ECT treatment to prevent an exacerbation of depres-
sion immediately after stopping ECT.
Safety and tolerability
The combination of ECT with TCAs and SSRIs has been
described as a safe procedure.
89,90 Safety data about the
combination of modern antidepressants with ECT are
available:in a recent study venlafaxine at dosages lower
than 300 mg/day has been shown to be safe in combina-
tion with ECT.In high-dose treatments above 300 mg/d,
side effects of cardiovascular nature such as transient
asystolia or bradycardia were more frequent if ECT was
combined with propofol anesthesia.
92The combination of
ECT with MAOIs should be treated with particular cau-
tion.It should be avoided if possible,due to the enhanced
risk of possibly lethal complications,especially shortly
after starting the pharmacological treatment.
93At least
the condition of a 2-week washout period should be
retained.The combination of ECT with lithium enhances
anesthesia risks,
94-96 the risk of prolonged seizures,
97 and
the risk of cognitive disturbances,but represents only a
relative contraindication due to reports of a safe use of




110Continuation ECT (C-ECT) in the long-term 
treatment of MDD
The terms continuation treatment and continuation ECT
(C-ECT) are predominantly used to characterize the
maintenance treatment after successful treatment of the
index phase.It is sometimes distinguished from mainte-
nance treatment and maintenance ECT (M-ECT)
99 due
to theoretical considerations about a switch to prophy-
lactic treatment preventing new episodes of depression.
This time point cannot be defined precisely in an indi-
vidual patient;therefore,in the following section only the
term C-ECT is used.
Besides pharmacologic and psychotherapeutic continua-
tion therapies,especially after pharmacotherapy treatment
failures, ECT is also an effective continuation treat-
ment,
43,99-101 even if the scientific evidence for use of ECT
as a maintenance treatment is limited due to an absence
of controlled studies.Continuation ECT should be con-
sidered in cases of recurrence of depressive symptoms
despite adequate pharmacologic continuation therapy or
in case of patients’ preference.Especially if the prior his-
tory of an individual patient shows an enhanced risk for
recurrence of depression during continued pharma-
cotherapy including both antidepressants and mood sta-
bilizers,C-ECT should be part of the treatment plan.
102-104
The usual clinical procedure is to prolong the treatment
intervals according to individual clinical requirements.
During the acute treatment,a patient usually receives two
or three treatments per week. Afterwards usually one
treatment per week is applied for 4 to 8 weeks,then one
treatment every 2 weeks,and then one treatment every 4
weeks.This frequency should be maintained for at least 6
months.A frequently used alternative strategy (the so-
called  cafeteria style) is the individual decision as to
whether an C-ECT treatment is administered when the
first signs of recurrence of depressive symptoms are
reported.
2,100 Regular weekly evaluations help to judge the
necessity of shortening the treatment-free intervals on an
individual basis.The same evaluation is necessary during
the attempt to stop ECT treatment after 6 months. As
soon as depressive symptoms reoccur,a prolongation of
the C-ECT should be applied.
ECT in the treatment of schizophrenia and
schizoaffective disorders
Electroconvulsive treatment of acute schizophrenia
ECT was introduced firstly as a treatment for schizo-
phrenia (for review see ref 105).Due to the subsequent
availability of antipsychotic medication,the use of ECT
in schizophrenic patients was notably reduced,in spite of
sufficient evidence for the efficacy of ECT in the acute
treatment reported in a variety of reviews and meta-
analyses.
106-108 According to these reports, ECT may be
considered for schizophrenic patients,especially when
rapid improvement and symptom reduction is desired.
In an extensive Cochrane review compared with simu-
lated ECT (sham ECT) as a placebo condition, more
patients showed improvement after receiving ECT.
108 In
the short term fewer relapses and a greater likelihood of
an earlier discharge from the hospital have also been
reported.Unfortunately insufficient evidence exists as to
whether this early advantage of ECT can be maintained
over the medium to long term.
Similar to other reports
103 limited evidence suggests that
greater improvement can be obtained combining ECT
with antipsychotic drugs.The combination of ECT with
antipsychotics was superior to either treatment alone.
106,108
Clozapine in particular seems to exert synergistic effects
with electroconvulsive treatment.
109-111
Comparing unilateral and bilateral stimulus administra-
tion,no clear advantage of bilateral ECT could be found.
An advantage of a longer treatment series with 20 elec-
troconvulsive treatments being more effective than 12
treatments has been reported.
108
Therefore,even though initial beneficial effects may not
last beyond the short term in each patient, ECT as an
additional treatment option can be recommended in
combination with an antipsychotic medication in treat-
ment-resistant schizophrenia.
Electroconvulsive treatment of acute schizoaffective
disorders
With regard to response to pharmacologic treatments,
schizoaffective disorders are similar to the primary affec-
tive disorders.
112 Similar to the switch risk in bipolar dis-
orders, in schizoaffective disorders mania may also be
induced by highly effective antidepressant treatments
including ECT.
70 Because a high rate of rapid treatment
response to electroconvulsive treatment of mania has
been reported,
78,113 ECT is suitable in both bipolar manic
and schizomanic episodes.In spite of the reported rapid
relief of symptoms,
113 ECT in schizoaffective disorders
has also been associated with poorer outcome in com-
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parison with the treatment of affective disorders.
114
Nevertheless,good clinical effectiveness in both schizo-
phrenia and schizoaffective disorders has been reported
in case series.
115,116 In addition, in very large Cochrane
reviews,the effectiveness of ECT in schizoaffective dis-
orders has been confirmed.
108 Again in case of nonre-
sponsiveness to clozapine due to good effectiveness,the
combination with ECT has been recommended for the
treatment of schizoaffective disorders.
109
Continuation ECT (C-ECT) in the long-term treatment
of schizophrenia and schizoaffective disorders
Due to high relapse rates, even in cases of sufficient
relapse prevention using adequate neuroleptic treat-
ment
117 continuation (and maintenance) ECT should be
considered as an effective treatment option in case of
schizophrenia
103,118 or schizoaffective disorders.
119 Even if
the lack of sufficient evidence for cost-effectiveness and
superiority of ECT over neuroleptic continuation treat-
ment has been considered,
120 and resource-intensive C-
ECT may not be a practical solution for some patients,
103
it is still an option in preventing relapse in patients not
responding sufficiently to pharmacotherapeutic relapse
prevention.It should therefore be offered to this selected
patient collective.
103,118 Patients referred for C-ECT should
have been responsive to ECT during the acute treatment
of their index episode and C-ECT should be considered
especially in the case of patients preference or in the case
of treatment resistance or intolerance to pharmacother-
apeutic continuation treatment.
40
The safety of ECT
In general, ECT is one of the best-tolerated biological
therapies with low risk for severe complications, even
lower than during the application of TCA.
2;40The mortal-
ity rate during ECT varies between 1:50 000 and 1:25 000
treatments.
2;40 In less than one in 10 000 treatments severe
complications are seen that warrant special attention.
40
ECT therefore is considered to be one of the safest med-
ical procedures under anesthesia. Clinical conditions
requiring special attention before and during ECT,
described in refs 2,3,are summarized in Table III.
Side effects
Somatic side effects
The most frequent immediate unpleasant effects of ECT
are headache,nausea,and vomiting (varying with anes-
thetic).Up to 45% of patients report headache which can
be treated symptomatically using analgesics such as
acetylsalicylic acid or paracetamol and, if severe, by
Table III. Relative contraindications—clinical conditions requiring special attention before and during ECT. *bold: previously considered as absolute
contraindications; today an individual risk/benefit-analysis is necessary
Category Clinical condition
Enhanced intracerebral pressure* at present
Cerebral infarction* not older than 3 months
Myocardial infarction* not older than 3 months
Intracerebral tumor* including intracerebral edema
Any life-threatening anesthesia risk* at present
Cardiovascular disorders cardiac arrhythmias, coronary artery disease and instable angina pectoris, myocardial 
infarction (older than 3 months), myocardial insufficiency, heart valve abnormalities, 
not sufficiently treated hyper-or hypotonia, aortal aneurysm
Medical disorders disturbance of blood coagulation, severe liver diseases, severe pulmonal diseases, 
pheochromocytoma
Neurological disorders intracerebral neoplasias, intracranial bleeding, intracerebral vascular malformations, 
cerebral ischemia, cerebral inflammations, hydrocephalus (also normal pressure 
hydrocephalus with risk for herniation), dementias, diseases of the basal ganglia, 
craniotomies, severe cerebral traumas
Orthopedic disorders osteoporosis
Esophageal hernia increased aspiration risk; intubation recommended
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changing the induction medications.Patients suffering
from regular migraine attacks are predisposed to postic-
tal headache after ECT.In this case triptans,eg,suma-
triptan, can be applied orally or intranasally.
121 Nausea
occurs rarely after anesthesia,and can be treated using
metoclopramide.Other rare complications of ECT can
be cardiovascular events emerging from anesthesia.On
rare occasions,the seizure is prolonged beyond the antic-
ipated 30 to 180 seconds.
40 This risk is considerably
enhanced in patients receiving theophylline.
97,122,123 The
treating anesthesiologist or psychiatrist will end the
seizure by the administration of intravenous benzodi-
azepines (eg diazepam), anesthetics, or other anticon-
vulsants.This event is best managed by ictal and postic-
tal electroencephalographic (EEG) monitoring,
123 which
can be of use also in the treatment of nonconvulsive
seizures which rarely occur after ECT.
122,123
In case of prolonged effectiveness of muscle relaxants
due to predisposition or lithium therapy
95,96 longer
assisted respiration and subsequent measurement of oxy-
gen saturation using finger or toe pulse oxymetry is nec-
essary to prevent hypoxia.Aching muscles are prevented
by adequate muscle relaxation,and were reported rarely.
In patients suffering from bipolar depression ECT like
any other antidepressant agent
121 can induce hypomania
or mania (“switch”).
121 Concomitant lithium therapy
73 can
be used despite the higher risk of side effects such as pro-
longed muscle relaxation and confusional states.The use
of mood stabilizers such as lamotrigine,valproate,or car-
bamazepine is possible despite the anticonvulsant prop-
erties of these agents.
73 Both methods can reduce the
switch risk significantly.
Cognitive side effects
All patients are confused on awakening after a seizure.
The duration and the severity of the post-seizure delir-
ium vary with patient age (older patients have more
severe and more prolonged periods of confusion),dosage
and type of anesthetic,and the characteristics of the med-
ications,both psychoactive and systemic,which may be
prescribed for the patients.Special attention is paid to
sedatives and anxiolytics,antipsychotics,and lithium that
may augment the confusional syndrome.
Typical side effects which are more prominent in bilat-
eral than in unilateral and in high-dose than in lower
dose ECT
4 are transient cognitive disturbances.These
include short-term memory disturbances in up to 30% of
the treated patients.
124 Postictal delirium including a pro-
longed reorientation period and memory disturbances
including anterograde or retrograde amnesia can be dif-
ferentiated from rarely occurring effects on the autobio-
graphic long-term memory.
125 In addition, cognitive
deficits not emerging from memory disturbances,such as
concentration or attention deficits,can occur.It can be
difficult in an individual patient to differentiate the cog-
nitive side effects of an ECT treatment from cognitive
disturbances caused by depression itself.
126Therefore a
variety of patients report amelioration of cognitive
impairment after an ECT treatment course.
127
As described, the rate of cognitive disturbances is
dependent on dose and application of electrical stimu-
lation.
85,127 Sometimes patients experience profound and
sustained memory loss,sufficient to interfere with their
ability to return to work.Such instances are rare,but are
the principal burden of the complaints against the use
of ECT.
2;41
Nevertheless, recent improvements in the use of ECT
include methods to maintain good therapeutic efficacy
together with a better tolerability concerning cognitive
disturbances.Using modified ECT techniques,
128 includ-
ing unilateral or bifrontal pulse wave stimulation,anes-
thesia with muscle relaxation,and sufficient oxygenation,
these risks could be reduced substantially.
64,68,128
If, in spite of these precautions, cognitive disturbances
occur,a rapid improvement within 1 and up to 4 weeks
can be observed in most cases.
128 Follow-up investigations
showed a complete reversibility of cognitive side effects
after an ECT course
128,129 or even an improvement in com-
parison with the time interval before ECT treatment.
3,129
A variety of case reports,case series,and controlled stud-
ies confirm that ECT does not cause long-lasting func-
tional
54 or any structural damage of the central nervous
system.
127,129,130
Clinical precautions and special considerations
After many decades of research and clinical experience,
clinicians have developed protocols for the safe treat-
ment of patients warranting ECT regardless of age,med-
ical status,or physical state.In the long term,after ade-
quate treatment of medical conditions enhancing somatic
risks, no absolute contraindications are acknowledged
(conditions including higher somatic risks are described
in Table II). In addition, every other untreated severe
medical and life-threatening anesthesiological risk has tobe taken into account.If treated insufficiently,these con-
ditions become relative contraindications,and an indi-
vidual and interdisciplinary benefit/risk analysis has to
be performed for each patient. In general, each factor
enhancing the risk for ECT or anesthesia should be
taken into consideration.In case of the described specific
risks interdisciplinary counseling may be necessary.
Afterwards the higher somatic risk has to be compared
with the risk of an insufficiently treated or prolonged
psychiatric illness.Patients and relatives or responsible
legal guardians have to be informed about risk:benefit
ratios to contribute to a shared decision.
Conclusion
ECT is a nonpharmacologic biological treatment which
has been proven to be a highly effective treatment option
predominantly for depression,but also for schizophrenia
in a variety of controlled investigations.This is not only
true in acute treatments; ECT can also be used for
relapse prevention during maintenance therapies.
In addition,the safety and tolerability of electroconvul-
sive treatment have been enhanced by using modified
stimulation techniques and by progress in modern anes-
thesia.During recent years,clinical conditions considered
as absolute contraindications for ECT in former times
became relative contraindications. Thus, today a safe
treatment can also be offered to patients with higher
somatic risks.
Recent research has contributed to an enhancement of
the knowledge of possible mechanisms of action of ECT
and to a safe and well tolerated treatment,but unfortu-
nately the final clarification of the underlying crucial
mechanisms still remains unresolved.Nevertheless,this
highly effective therapeutic option should not kept back,
especially from patients suffering from psychiatric ill-
nesses which are unresponsive to other treatments.ECT
still represents an important option in the therapy of
treatment-resistant depression.
Thorough information provision in hospitals,and also the
growing objective and unbiased information in the press
and other media,could contribute to fighting the  prej-
udice and stigma of psychiatric disorders and specific
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Terapia electroconvulsiva y sus diferentes
indicaciones
A pesar de los recientes progresos en la farmacote-
rapia de los trastornos depresivos aun persisten sin
resolverse dos importantes problemas: la latencia
hasta alcanzar la mejoría clínica, y la alta frecuen-
cia de falta de respuesta y de remisión. La terapia
electroconvulsiva (TEC) es un tratamiento biológico
no farmacológico que ha probado ser una opción
terapéutica altamente efectiva, preferentemente
para la depresión, pero también para la esquizo-
frenia y otras indicaciones. Aunque faltan investi-
gaciones controladas en tratamientos a largo plazo,
la TEC también puede ser empleada en prevención
de recaídas durante las terapias de mantenimiento.
La seguridad y tolerabilidad del tratamiento elec-
troconvulsivo han aumentado con el uso de técni-
cas de estimulación modificadas y por el progreso
de la moderna anestesia. De esta manera hoy en
día también se puede ofrecer un tratamiento
seguro a pacientes que tienen mayores riesgos
somáticos. La TEC aun representa una importante
opción, especialmente en el manejo de pacientes
con trastornos psiquiátricos resistentes al trata-
miento después de fallar la terapia medicamentosa.
Con las consideraciones anteriores la TEC puede
reducir la frecuencia de trastornos psiquiátricos cró-
nicos y difíciles de tratar. 
L’électroconvulsivothérapie et ses 
différentes indications
Malgré les récents développements dans le
domaine de la pharmacothérapie de la dépression,
la latence de survenue de l’amélioration clinique et
le taux considérable d’absence de réponse et de
rémission sont des problèmes majeurs non résolus
à ce jour. L’électroconvulsivothérapie (ECT) est un
traitement biologique non pharmacologique qui a
prouvé sa grande efficacité thérapeutique surtout
dans la dépression mais aussi dans la schizophrénie
et d’autres indications. En dépit d’un manque
d’études contrôlées sur les traitements à long
terme, l’ECT peut être également utilisé dans la pré-
vention des rechutes au cours des traitements d’en-
tretien. Les progrès de l’anesthésie moderne et les
techniques de stimulation dites modifiées ont amé-
lioré la tolérance et la sécurité d’emploi de l’ECT.
Aujourd’hui, un traitement sûr peut donc être pro-
posé aux patients à risque somatique plus élevé.
L’ECT reste une alternative importante surtout dans
le traitement des troubles psychiatriques résistants
au traitement en cas d’échec thérapeutique anté-
rieur. Envisager l’ECT de façon précoce pourrait
diminuer le taux de troubles psychiatriques chro-
niques difficiles à traiter.Clinical research
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